Market Research Logo

The Global Market for Adjunctive Therapies in Cancer


Attention: There is an updated edition available for this report.

The Global Market for Adjunctive Therapies in Cancer provides the reader with a comprehensive analysis of the domestic and international markets involving pharmaceuticals to treat and manage symptoms in cancer patients. Market information is available for the years 1996 to 2006, with the focus year 2001. Overview and product descriptions of general adjunctive therapy segments are covered, including:

  • antinauseants and antiemetics
  • pain management
  • blood modifiers
  • infection control; and
  • other therapies.

The study covers issues and trends affecting the market, research and developments, demographics, cancer statistics and more. Profiles of major market participants are included.


Press Release

Biological Response Modifiers Outpace Other Therapeutics in Worldwide Cancer Adjuncts Market

New York, April 23, 2002 /PR Newswire — The market for biological response modifiers (BRMs) continues to grow more rapidly than all other adjunctive therapy segments and should pass the $10 billion market by 2005, according to a new study released today from Kalorama Information and available at MarketResearch.com. The BRM segment has seen double-digit growth over the past few years, and the study predicts that this trend should continue.

The new study entitled The Global Market for Adjunctive Therapies in Cancer found that in addition to BRMs, other segments in adjunctive therapy are also showing strong growth. Pain management for both primary and breakthrough cancer pain will grow by more than 10% annually for the next few years, and should surpass $4.5 billion by 2006. The market for products for breakthrough pain, in particular, is growing very rapidly, and will see growth rates as high as 47% in the next few years.

“The adjunctive therapy market is benefiting from several industry-wide trends,” notes Steven Heffner, acquisitions editor at Kalorama Information. “It’s one of the first markets in which new biopharmaceuticals are having great success, and it’s also one of the first markets to experience the impact of new drug delivery technologies, which are driving fierce competition in the breakthrough pain segment.”

The Global Market for Adjunctive Therapies in Cancer represents new primary research into the major adjunctive therapy market segments, including BRMs, pain management products, antiemetics and antinauseants, infection control products, and other adjunctive therapies. The study analyzes the market globally and regionally and discusses trends and competitors.

Chapter One: Executive Summary


    Introduction
    Scope and Methodology
    Size and Growth Of The Market
    Issues and Trends Affecting The Global Market
    Leading Competitors

Chapter Two: Introduction


    Overview of Cancer
    • Biology of Cancer
    • Treatments and Symptoms

    Types of Products and Administration
    Demographics, Prevalence, Incidence, Mortality

Chapter Three: Issues and Trends


    Overview
    Geographical Trends
    • United States

    Regulatory Authorities
    • Clinical Trials
    • New Indications

    Direct-To-Consumer Advertising
    Lifestyle and Social Issues
    Barriers To Adjunctive Therapies
    Drug Delivery Advancements
    Pain Management Measures
    Oxycontin Issues
    Cancer-Related Fatigue Issues
    Individualized Chemotherapy
    Chemotherapy and Memory Loss

Chapter Four: Antinauseants and Antiemetics


    Overview
    Products
    • Serotonin Receptor Antagonists
    • Phenothiazines
    • Metoclopramide and Other Drugs

    Drug Delivery Methods For Antinauseants and Antiemetics
    Research And Development
    Market Overview By Geographic Region
    • United States
    • Europe
    • Japan
    • Rest of World

    Competitive Analysis

Chapter Five: Pain Management


    Overview
    • Pain Pathways
    • Primary Cancer Pain
    • Breakthrough Cancer Pain
    • Cancer Pain Delivery Methods

    Description of Products
    • Primary Cancer Pain Medications
    • Breakthrough Cancer Pain Medications

    Research and Development
    Market Overview By Geographic Region
    • United States
    • Europe
    • Japan
    • Rest of World

    Competitive Analysis

Chapter Six: Biological Response Modifiers


    Overview
    Description of Products
    • Hematopoietic Growth Factors
    • Cytomodulatory Agents

    Research And Development
    Market Overview By Geographic Region
    • United States
    • Europe
    • Japan
    • Rest of World

    Competitive Analysis

Chapter Seven: Infection Control


    Overview
    Description of Products
    • Anti-Infectives
    • Antifungals

    Research And Development
    Market Overview By Geographic Region
    • United States
    • Europe
    • Japan
    • Rest of World

    Competitive Analysis

Chapter Eight: Other Adjunctive Therapies


    Overview
    Description of Products
    • Fatigue
    • Anorexia/Cachexia/Weight Loss
    • Diarrhea
    • Constipation
    • Hair Loss

    Research And Development
    Market Overview By Geographic Region
    • United States
    • Europe
    • Japan
    • Rest of World

    Competitive Analysis

Chapter Nine: Total Market Size and Forecast


    Overview
    Total Market Size and Forecast
    • Market By Segment
    • Market By Region

    Competitive Analysis
    Market Analysis

Chapter Ten: Company Profiles


    Introduction
    Competitive Summary
    Abbott Laboratories
    Amgen, Inc.
    Aventis
    Bayer Corporation
    Chugai Pharmaceutical Company Ltd.
    Eli Lilly & Company
    Glaxosmithkline Plc
    Johnson & Johnson
    Kirin Brewery Company Ltd.
    Knoll Pharmaceuticals Company (Abbott Laboratories)
    Novartis Pharmaceuticals Corporation
    Pfizer, Inc.
    Roche Group
    Roxane Laboratories, Inc.

Appendix: Company Directory

List of Exhibits


    Table 1-1: Cancer Incidence and Deaths as a Percentage to Population by Selected Country/Region 2001
    Table 1-2: The Global Market for Adjunctive Therapies in Cancer by Type, 1996-2006
    Figure 1-1: The Global Market for Adjunctive Therapies in Cancer Revenues by Type 1996-2006
    Figure 1-2: The Global Market for Adjunctive Therapies in Cancer Distribution by Type 1996-2006
    Table 2-1: List of Cancers
    Table 2-2: Side Effects Associated with Chemotherapy
    Table 2-3: Side Effects Associated with Radiation Therapy
    Table 2-4: Population by Country 1996-2006
    Figure 2-1: Population by Significant Country 1996, 2001, 2006
    Table 2-5: Cancer Prevalence by Country 1996-2001
    Figure 2-2: Cancer Prevalence by Country 1996-2001
    Table 2-6: Cancer Incidence by Country 1996-2001
    Figure 2-3: Cancer Incidence by Country 1996-2001
    Table 2-7: Cancer Deaths by Country 1996-2001
    Figure 2-4: Cancer Deaths by Country
    Table 2-8: Cancer Incidence and Deaths as a Percentage to Population by Selected Country/Region 2001
    Table 2-9: Cancer Incidence by Type and Country 2001
    Table 2-10: Cancer Deaths by Type and Country 200141
    Figure 4-1: Incidence of Emesis in Cancer Patients
    Table 4-1: Chemotherapy Agents and Level of Emetic Potential
    Table 4-2: Selected Prescription Antinauseants, Antiemetics and Others with Antiemetic Properties by Available Delivery Method
    Table 4-3: Antinauseants and Antiemetics in Development for Treatment of Cancer related Nausea and Vomiting
    Table 4-4: The Global Market for Adjunctive Therapies in Cancer: Antinauseants and Antiemetics 1996-2006
    Figure 4-2: The Global Market for Adjunctive Therapies in Cancer: Antinauseants and Antiemetics 1996-2006
    Table 4-5: The Global Market for Adjunctive Therapies in Cancer: Antinauseants and Antiemetics by Geographic Region 1996-2006
    Table 4-6: The Global Market for Adjunctive Therapies in Cancer: Antinauseants and Antiemetics Share of Global Market by Geographic Region 1996-2006
    Figure 4-3: The Global Market for Adjunctive Therapies in Cancer: Antinauseants and Antiemetics, by Geographic Region, 1996-2006
    Figure 4-4: The Global Market for Adjunctive Therapies in Cancer: Antinauseants and Antiemetics, Share by Geographic Region 2001
    Table 4-7: U.S. Market for Adjunctive Therapies in Cancer: Antinauseants and Antiemetics 1996-2006
    Figure 4-5: U.S. Market for Adjunctive Therapies in Cancer: Antinauseants and Antiemetics 1996-2006
    Table 4-8: European Market for Adjunctive Therapies in Cancer: Antinauseants and Antiemetics 1996-2006
    Figure 4-6: European Market for Adjunctive Therapies in Cancer: Antinauseants and Antiemetics 1996-2006
    Table 4-9: Japanese Market for Adjunctive Therapies in Cancer: Antinauseants and Antiemetics 1996-2006
    Figure 4-7: Japanese Market for Adjunctive Therapies in Cancer: Antinauseants and Antiemetics 1996-2006
    Table 4-10: Rest of World Market for Adjunctive Therapies in Cancer: Antinauseants and Antiemetics 1996-2006
    Figure 4-8: Rest of World Market for Adjunctive Therapies in Cancer: Antinauseants and Antiemetics 1996-2006
    Table 4-11: Leading Suppliers’ Shares of the Global Market for Adjunctive Therapies in Cancer: Antinauseants and Antiemetics
    Figure 4-9: Leading Suppliers’ Shares of the Global Market for Adjunctive Therapies in Cancer: Antinauseants and Antiemetics
    Figure 5-1: Incidence of Pain in Cancer Patients
    Table 5-1: The World Health Organization Three-Step Analgesic Ladder
    Table 5-2: Selected Prescription Non-Narcotic Analgesics by Available Delivery Method
    Table 5-3: Selected Over-the-Counter Non-Narcotic Analgesics by Available Delivery Method
    Table 5-4: Selected Prescription Narcotic Analgesics by Available Delivery Method
    Table 5-5: Selected Prescription Antidepressants Used for Cancer Pain by Available Delivery Method
    Table 5-6: Selected Prescription Anticonvulsants Used for Cancer Pain by Available Delivery Method
    Table 5-7: Selected Prescription Corticosteroids Used for Cancer Pain by Available Delivery Method
    Table 5-8: Selected Prescription Bisphosphonates and Calcitonins Used for Cancer Pain by Available Delivery Method
    Table 5-9: Selected Prescription Radiopharmacuticals Used for Cancer Pain by Available Delivery Method
    Table 5-10: Pain Management Products in Development for Treatment of Cancer Related Pain
    Table 5-11: The Global Market for Adjunctive Therapies in Cancer: Pain Management 1996-2006
    Figure 5-2: The Global Market for Adjunctive Therapies in Cancer: Pain Management 1996-2006
    Table 5-12: The Global Market for Adjunctive Therapies in Cancer: Pain Management, by Geographic Region 1996-2006
    Table 5-13: The Global Market for Adjunctive Therapies in Cancer: Pain Management Products Share of Global Market by Geographic Region 1996-2006
    Figure 5-3: The Global Market for Adjunctive Therapies in Cancer: Pain Management by Geographic Region 1996-2006
    Figure 5-4: The Global Market for Adjunctive Therapies in Cancer: Pain Management, by Percent and Geographic Region 2001
    Table 5-14: The Global Market for Adjunctive Therapies in Cancer: Pain Management by Pain Type 1996-2006
    Table 5-15: The Global Market for Adjunctive Therapies in Cancer: Pain Management Market Share by Pain Type 1996-2006
    Figure 5-5: The Global Market for Adjunctive Therapies in Cancer: Pain Management, by Pain Type, 1996-2006
    Figure 5-6: The Global Market for Adjunctive Therapies in Cancer: Pain Management, by Pain Type 2001
    Table 5-16: U.S. Market for Adjunctive Therapies in Cancer: Pain Management 1996-2006
    Figure 5-7: U.S. Market for Adjunctive Therapies in Cancer: Pain Management 1996-2006
    Table 5-17: European Market for Adjunctive Therapies in Cancer: Pain Management 1996-2006
    Figure 5-8: European Market for Adjunctive Therapies in Cancer: Pain Management 1996-2006
    Table 5-18: Japanese Market for Adjunctive Therapies in Cancer: Pain Management 1996-2006
    Figure 5-9: Japanese Market for Adjunctive Therapies in Cancer: Pain Management 1996-2006
    Table 5-19: Rest of World Market for Adjunctive Therapies in Cancer: Pain Management 1996-2006
    Figure 5-10: Rest of World Market for Adjunctive Therapies in Cancer: Pain Management 1996-2006
    Table 5-20: Leading Suppliers’ Shares of the Global Market for Adjunctive Therapies in Cancer: Pain Management 2001
    Figure 5-11: Leading Suppliers’ Shares of the Global Market for Adjunctive Therapies in Cancer: Pain Management, 2001
    Figure 6-1: Frequency of Bone Marrow Suppression in Cancer Patients
    Table 6-1: Selected Biological Response Modifiers, and Available Delivery Method
    Table 6-2: Biological Response Modifiers in Development for Treatment of Cancer related Infection
    Table 6-3: The Global Market for Adjunctive Therapies in Cancer: Biological Response Modifiers 1996-2006
    Figure 6-2: The Global Market for Adjunctive Therapies in Cancer: Biological Response Modifiers
    Table 6-4: The Global Market for Adjunctive Therapies in Cancer: Biological Response Modifiers by Geographic Region 1996-2006
    Table 6-5: The Global Market for Adjunctive Therapies in Cancer: Biological Response Modifiers Share by Geographic Region, 1996-2006
    Figure 6-3: The Global Market for Adjunctive Therapies in Cancer: Biological Response Modifiers by Geographic Region 1996-2006
    Figure 6-4: The Global Market for Adjunctive Therapies in Cancer: Biological Response Modifiers Share by Geographic Region 2001
    Table 6-6: The U.S. Market for Adjunctive Therapies in Cancer: Biological Response Modifiers 1996-2006
    Figure 6-5: The U.S. Market for Adjunctive Therapies in Cancer: Biological Response Modifiers 1996-2006
    Table 6-7: European Market for Adjunctive Therapies in Cancer: Biological Response Modifiers 1996-2006
    Figure 6-6: European Market for Adjunctive Therapies in Cancer: Biological Response Modifiers 1996-2006
    Table 6-8: Japanese Market for Adjunctive Therapies in Cancer: Biological Response Modifiers 1996-2006
    Figure 6-7: Japanese Market for Adjunctive Therapies in Cancer: Biological Response Modifiers 1996-2006
    Table 6-9: Rest of World Market for Adjunctive Therapies in Cancer: Biological Response Modifiers 1996-2006
    Figure 6-8: Rest of World Market for Adjunctive Therapies in Cancer: Biological Response Modifiers 1996-2006
    Table 6-10: Leading Suppliers’ Shares of the Global Market for Adjunctive Therapies in Cancer Biological Response Modifiers 2001
    Figure 6-9: Leading Suppliers’ Shares of the Global Market for Adjunctive Therapies in Cancer Biological Response Modifiers 2001
    Table 7-1: Common Infection Sites and Organisms
    Figure 7-1: Frequency of Infection in Cancer Patients
    Table 7-2: Selected Prescription Anti-infective Agents and Available Delivery Methods
    Table 7-3: Selected Prescription Antifungals and Available Delivery Method
    Table 7-4: Anti-Infective Agents and Antifungals in Development for Treatment of Cancer related Infection
    Table 7-5: The Global Market for Adjunctive Therapies in Cancer: Infection Control 1996-2006
    Figure 7-2: The Global Market for Adjunctive Therapies in Cancer: Infection Control, 1996-2006
    Table 7-6: The Global Market for Adjunctive Therapies in Cancer: Infection Control by Geographic Region 1996-2006
    Table 7-7: The Global Market for Adjunctive Therapies in Cancer: Infection Control Share by Geographic Region 1996-2006
    Figure 7-3: The Global Market for Adjunctive Therapies in Cancer: Infection Control by Geographic Region 1996-2006
    Figure 7-4: The Global Market for Adjunctive Therapies in Cancer: Infection Control Share by Geographic Region 2001
    Table 7-8: The Global Market for Adjunctive Therapies in Cancer: Infection Control by Type 1996-2006
    Table 7-9: The Global Market for Adjunctive Therapies in Cancer: Infection Control Share by Type 1996-2006
    Figure 7-5: The Global Market for Adjunctive Therapies in Cancer: Infection Control by Product Type 1996-2006
    Figure 7-6: The Global Market for Adjunctive Therapies in Cancer: Infection Control by Product Type 2001
    Table 7-10: U.S. Market for Adjunctive Therapies in Cancer: Infection Control 1996-2006
    Figure 7-7: U.S. Market for Adjunctive Therapies in Cancer: Infection Control 1996-2006
    Table 7-11: European Market for Adjunctive Therapies in Cancer: Infection Control 1996-2006
    Figure 7-8: European Market for Adjunctive Therapies in Cancer: Infection Control 1996-2006
    Table 7-12: Japanese Market for Adjunctive Therapies in Cancer: Infection Control 1996-2006
    Figure 7-9: Japanese Market for Adjunctive Therapies in Cancer: Infection Control 1996-2006
    Table 7-13: Rest of World Market for Adjunctive Therapies in Cancer: Infection Control 1996-2006
    Figure 7-10: Rest of World Market for Adjunctive Therapies in Cancer: Infection Control 1996-2006
    Table 7-14: Leading Suppliers’ Share of the Global Market for Adjunctive Therapies in Cancer: Infection Control 2001
    Figure 7-11: Leading Suppliers’ Share of the Global Market for Adjunctive Therapies in Cancer: Infection Control 2001
    Figure 8-1: Frequency of Fatigue in Cancer Patients
    Figure 8-2: Incidence of Anorexia/Cachexia/Weight Loss in Cancer Patients
    Figure 8-3: Incidence of Diarrhea in Cancer Patients
    Figure 8-4: Incidence of Constipation in Cancer Patients
    Table 8-1: Selected Chemotherapy Agents and Level of Hair Loss Potential
    Figure 8-5: Frequency of Hair Loss in Cancer Patients
    Figure 8-6: Prevalence of Various Conditions in Cancer Patients
    Table 8-2: Selected Prescription and Non-prescription Products to Minimize Symptoms of Fatigue in Cancer Patients and Available Delivery Method
    Table 8-3: Selected Prescription Products for the Treatment of Anorexia/Cachexia in Cancer Patients and Available Delivery Method
    Table 8-4: Selected Prescription and Non-prescription Products for the Treatment of Diarrhea in Cancer Patients and Available Delivery Method
    Table 8-5: Selected Prescription and Non-prescription Products for the Treatment of Constipation in Cancer Patients and Available Delivery Method
    Table 8-6: Other Adjunctive Therapies in Development for Treatment of Cancer
    Table 8-7: The Global Market for Adjunctive Therapies in Cancer: Other Therapies 1996-2006
    Figure 8-7: The Global Market for Adjunctive Therapies in Cancer: Other Therapies 1996-2006
    Table 8-8: The Global Market for Adjunctive Therapies in Cancer: Other Therapies, by Geographic Region, 1996-2006
    Table 8-9: The Global Market for Adjunctive Therapies in Cancer Other Therapies Distribution by Geographic Region 1996-2006
    Figure 8-8: The Global Market for Adjunctive Therapies in Cancer: Other Therapies by Geographic Region 1996-2006
    Figure 8-9: The Global Market for Adjunctive Therapies in Cancer: Other Therapies Distribution by Geographic Region 2001
    Table 8-10: U.S. Market for Adjunctive Therapies in Cancer: Other Therapies 1996-2006
    Figure 8-10: U.S. Market for Adjunctive Therapies in Cancer: Other Therapies 1996-2006
    Table 8-11: European Market for Adjunctive Therapies in Cancer: Other Therapies 1996-2006
    Figure 8-11: European Market for Adjunctive Therapies in Cancer: Other Therapies 1996-2006
    Table 8-12: Japanese Market for Adjunctive Therapies in Cancer: Other Therapies 1996-2006
    Figure 8-12: Japanese Market for Adjunctive Therapies in Cancer: Other Therapies 1996-2006
    Table 8-13: Rest of World Market for Adjunctive Therapies in Cancer: Other Therapies 1996-2006
    Figure 8-14: Rest of World Market for Adjunctive Therapies in Cancer: Other Therapies 1996-2006
    Table 9-1: The Global Market for Adjunctive Therapies in Cancer by Type, 1996-2006
    Table 9-2: The Global Market for Adjunctive Therapies in Cancer Distribution by Type 1996-2006
    Figure 9-1: The Global Market for Adjunctive Therapies in Cancer Revenues by Type 1996-2006
    Figure 9-2: The Global Market for Adjunctive Therapies in Cancer by Type and Percent Distribution, 1996-2006
    Figure 9-3: The Global Market for Adjunctive Therapies in Cancer Distribution by Type 2001
    Table 9-3: The Global Market for Adjunctive Therapies in Cancer by Geographical Region, 1996-2006
    Table 9-4: The Global Market for Adjunctive Therapies in Cancer Distribution by Geographical Region 1996-2006
    Figure 9-4: The Global Market for Adjunctive Therapies in Cancer Revenues by Geographical Region 1996-2006
    Figure 9-5: The Global Market for Adjunctive Therapies in Cancer by Geographical Region and Percent Distribution, 1996-2006
    Figure 9-6: The Global Market for Adjunctive Therapies in Cancer by Percent and Geographical Region, 2001
    Table 9-5: Leading Suppliers, Products, and Segments of Participation 2001

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report